These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 17395784)

  • 1. Absence of donor T-cell-derived soluble TNF decreases graft-versus-host disease without impairing graft-versus-tumor activity.
    Borsotti C; Franklin AR; Lu SX; Kim TD; Smith OM; Suh D; King CG; Chow A; Liu C; Alpdogan O; van den Brink MR
    Blood; 2007 Jul; 110(2):783-6. PubMed ID: 17395784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine.
    Waldman E; Lu SX; Hubbard VM; Kochman AA; Eng JM; Terwey TH; Muriglan SJ; Kim TD; Heller G; Murphy GF; Liu C; Alpdogan O; van den Brink MR
    Blood; 2006 Feb; 107(4):1703-11. PubMed ID: 16291587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation.
    Tsukada N; Kobata T; Aizawa Y; Yagita H; Okumura K
    Blood; 1999 Apr; 93(8):2738-47. PubMed ID: 10194454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.
    Hill GR; Teshima T; Gerbitz A; Pan L; Cooke KR; Brinson YS; Crawford JM; Ferrara JL
    J Clin Invest; 1999 Aug; 104(4):459-67. PubMed ID: 10449438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.
    Lu SX; Kappel LW; Charbonneau-Allard AM; Atallah R; Holland AM; Turbide C; Hubbard VM; Rotolo JA; Smith M; Suh D; King C; Rao UK; Yim N; Bautista JL; Jenq RR; Penack O; Na IK; Liu C; Murphy G; Alpdogan O; Blumberg RS; Macian F; Holmes KV; Beauchemin N; van den Brink MR
    PLoS One; 2011; 6(7):e21611. PubMed ID: 21760897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
    Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
    J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
    Anderson LD; Mori S; Mann S; Savary CA; Mullen CA
    Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation.
    Tawara I; Koyama M; Liu C; Toubai T; Thomas D; Evers R; Chockley P; Nieves E; Sun Y; Lowler KP; Malter C; Nishimoto N; Hill GR; Reddy P
    Clin Cancer Res; 2011 Jan; 17(1):77-88. PubMed ID: 21047980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adult thymus transplantation with allogeneic intra-bone marrow-bone marrow transplantation from same donor induces high thymopoiesis, mild graft-versus-host reaction and strong graft-versus-tumour effects.
    Miyake T; Hosaka N; Cui W; Nishida T; Takaki T; Inaba M; Kamiyama Y; Ikehara S
    Immunology; 2009 Apr; 126(4):552-64. PubMed ID: 18778285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
    Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant CD95-Fc (APG101) prevents graft-versus-host disease in mice without disabling antitumor cytotoxicity and T-cell functions.
    Hartmann N; Messmann JJ; Leithäuser F; Weiswange M; Kluge M; Fricke H; Debatin KM; Strauss G
    Blood; 2013 Jan; 121(3):556-65. PubMed ID: 23203823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity.
    Ghosh A; Dogan Y; Moroz M; Holland AM; Yim NL; Rao UK; Young LF; Tannenbaum D; Masih D; Velardi E; Tsai JJ; Jenq RR; Penack O; Hanash AM; Smith OM; Piersanti K; Lezcano C; Murphy GF; Liu C; Palomba ML; Sauer MG; Sadelain M; Ponomarev V; van den Brink MR
    J Clin Invest; 2013 Jun; 123(6):2654-62. PubMed ID: 23676461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IFN-gamma and Fas ligand are required for graft-versus-tumor activity against renal cell carcinoma in the absence of lethal graft-versus-host disease.
    Ramirez-Montagut T; Chow A; Kochman AA; Smith OM; Suh D; Sindhi H; Lu S; Borsotti C; Grubin J; Patel N; Terwey TH; Kim TD; Heller G; Murphy GF; Liu C; Alpdogan O; van den Brink MR
    J Immunol; 2007 Aug; 179(3):1669-80. PubMed ID: 17641033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation.
    Schmaltz C; Alpdogan O; Muriglan SJ; Kappel BJ; Rotolo JA; Ricchetti ET; Greenberg AS; Willis LM; Murphy GF; Crawford JM; van den Brink MR
    Blood; 2003 Mar; 101(6):2440-5. PubMed ID: 12424195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solid Tumor-Induced Immune Regulation Alters the GvHD/GvT Paradigm after Allogenic Bone Marrow Transplantation.
    Dang N; Lin Y; Rutgeerts O; Sagaert X; Billiau AD; Waer M; Sprangers B
    Cancer Res; 2019 May; 79(10):2709-2721. PubMed ID: 30936086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptively transferred gamma delta T cells indirectly regulate murine graft-versus-host reactivity following donor leukocyte infusion therapy in mice.
    Drobyski WR; Vodanovic-Jankovic S; Klein J
    J Immunol; 2000 Aug; 165(3):1634-40. PubMed ID: 10903774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects.
    Olson JA; Leveson-Gower DB; Gill S; Baker J; Beilhack A; Negrin RS
    Blood; 2010 May; 115(21):4293-301. PubMed ID: 20233969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reconstructing immunity after allogeneic transplantation.
    Giver CR; Li JM; Hossain MS; Lonial S; Waller EK
    Immunol Res; 2004; 29(1-3):269-82. PubMed ID: 15181288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.